TELOMIR PHARMACEUTICALS, INC.

Telomir Pharmaceuticals' Telomir-1 fully reversed STAT1 gene silencing in aggressive prostate cancer cells, while Paclitaxel showed no effect and Rapamycin achieved only partial reduction.

Telomir-1 completely reversed epigenetic silencing of the STAT1 tumor suppressor gene in aggressive human prostate cancer cells during a 21-day preclinical study.

Telomir Pharmaceuticals has secured $3 million in premium equity financing from its largest shareholder to advance Telomir-1, a first-in-class age-reversal molecule, toward an IND submission for rare disease indications by year-end.

Telomir Pharmaceuticals has developed Telomir-Ag2, a stabilized Silver(II) complex showing potent activity against drug-resistant pathogens including MARSA, targeting the $30B+ antimicrobial market.

Telomir Pharmaceuticals' novel compound Telomir-1 demonstrates complete reversal of copper-induced oxidative stress in human cell lines, showing potential for treating age-related diseases and neurological disorders.

Telomir Pharmaceuticals' Telomir-1 demonstrated significant copper-binding affinity in preclinical studies, suggesting its potential for treating Wilson's disease.